CHAI’s latest market memo examines integrated HIV, syphilis, and hepatitis B screening in antenatal care across 16 countries and what it means for triple elimination.
Ferric carboxymaltose (FCM) outperforms standard oral iron for anemia in pregnancy but remains out of reach for most women in low- and middle-income countries. CHAI’s 15-country landscape report maps why, and what it will take to change it.
Twenty years ago, the experts said it couldn’t be done. Treating HIV in low-income countries was too expensive, too complicated. CHAI believed otherwise—and got to work.
The 2025 Family Planning Market Report presents an analysis of public-sector contraceptive procurement trends from 2020–2024, complemented by qualitative insights on the 2025 funding outlook following the dismantling of USAID and the anticipated impact of these...
26,000 children lost HIV treatment in 6 months. CHAI’s 2025 HIV Market Report shows funding cut impacts in 14 countries. Download data now.
By 2035, insulin treatment in LMICs will double to 76 million—but 30 million people will still lack access, our new market memo reveals.
CHAI has released new analysis examining contraceptive access across multiple African countries in the months following the end of USAID’s reproductive health programs in early 2025.
Tuberculosis (TB) is the world's deadliest infectious disease, killing over a million people annually. While the century-old BCG vaccine protects young children, it leaves adolescents and adults vulnerable—and they're the ones who are most likely to spread TB. New...
CHAI has released the inaugural edition of its Triple Elimination Series, a set of market briefs examining market-shaping strategies to prevent vertical transmission of HIV, syphilis, and hepatitis B (commonly known as triple elimination). This first brief focuses on...
The second edition of CHAI’s HIV Market Impact Memo highlights the ongoing impact of cuts to HIV services across low- and middle-income countries.
